Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
FHFoghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc. (FHTX)

NASDAQ Global Market · Currency in USD
$2.00 ▼ -0.01 (-0.50%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.00 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:10 PM ET

Summary

Previous Close
$2.01
Open
$1.95
Day's Range
$1.90 – $2.03
52 Week Range
$1.79 – $7.61
Volume
486,822
Avg. Volume
602,035
Market Cap
$118.77M
Beta (5Y Monthly)
3.01
PE Ratio (TTM)
--
EPS (TTM)
-$0.91
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$4.00

Profile: Foghorn Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
106
CEO
Adrian H. Gottschalk

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.23 · Revenue est. $6.39M
DateEst.Actual
Aug 6, 2026-$0.25-$0.10Beat
May 7, 2026-$0.28-$0.29Miss
Mar 11, 2026-$0.28-$0.34Miss
Nov 5, 2025-$0.31-$0.25Beat
Aug 5, 2025-$0.31-$0.28Beat
May 14, 2025-$0.30-$0.30Beat

Analyst view

Consensus price target
$4.00 ▲ +100.0%
Range $2.00 – $5.00
Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on FHTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.